Delenex Announces New Pre-Clinical Data Demonstrating Anti-Tumor Activity of DLX1008

News   May 29, 2015

 
Delenex Announces New Pre-Clinical Data Demonstrating Anti-Tumor Activity of DLX1008
 
 
 

RELATED ARTICLES

Patent Plausability Case Sees BIA Intervention

News

The UK Bioindustry Association (BIA) will intervene in a court case which could have huge ramifications for UK bioscience.

READ MORE

Pioneering Method Enables Screening Millions of Human Antibodies for Rapid Therapeutic Discovery

News

A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery.

READ MORE

Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News

An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE